Type 1 Diabetes

Patients with inflammatory bowel disease, type 1 diabetes and venous thromboembolism have an increased risk for rheumatoid arthritis, which in turn increases the risk for cardiovascular disease, obstructive sleep apnea and — again — venous thromboembolism, according to data published in Mayo Clinic Proceedings.

Each month Endocrine Today reporters ask leading endocrinologists and diabetes educators about their resesarch and practices. Some of our recent Q&As are below.

One of the week’s top stories in endocrinology was about a study that found adults with type 1 diabetes who used a higher glucose threshold for hypoglycemia alarms during continuous glucose monitor therapy spent approximately 50% less time in hypoglycemia.

In this issue, Susan Weiner, MS, RDN, CDE, CDN, FAADE, talks with clinical psychologist and diabetes educator Nicole M. Bereolos, PhD, MPH, MSCP, CDE.

The FDA on Tuesday approved an expanded indication for insulin glargine injection 300 U/mL to improve glucose response in children aged 6 years and older with diabetes, according to a press release from Sanofi.

The prevalence of type 1 diabetes among transgender and gender-nonconforming youths is more than nine times higher than that of the general population, with researchers exploring the role of increased psychological stress among adolescents with both diagnoses, according to findings from a single-center study published in Pediatric Diabetes.

A cohort of adults with type 1 diabetes using continuous glucose monitor therapy spent about 50% less time in hypoglycemia and 65% less time in severe hypoglycemia when using a higher glucose threshold for hypoglycemia alarms, according to findings from an observational study published in the Journal of the Endocrine Society.

A presentation at ObesityWeek that identified multiple benefits from a low-carbohydrate diet in patients with type 2 diabetes — including weight loss, lower HbA1c, and reduced insulin resistance and cardiovascular risk — was the top story in endocrinology last week.

Today marks World Diabetes Day, established in 1991 by the International Diabetes Federation and the World Health Organization to raise awareness of the growing number of people affected by the disease. The date November 14 is the birthday of insulin discoverer Sir Frederick Banting.

The Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 14-2 against recommending approval of a supplemental new drug application for the SGLT2 inhibitor empagliflozin 2.5 mg as an oral medication adjunct to insulin therapy for adults with type 1 diabetes, with committee members citing uncertainty regarding the adjudication of diabetic ketoacidosis and a lack of adequate data to support evidence for safety and efficacy.